ALBUQUERQUE, N.M., April 23 /PRNewswire-FirstCall/ --
Protalex, Inc. (OTC Bulletin Board: PRTX) recently filed a broad and
far-reaching patent application covering its unique approach to the treatment
of rheumatoid arthritis and other immune disorders. Capping two years of
animal studies and extensive research with in vitro systems, the patent
addresses an entirely new concept of therapy for diseases notoriously
difficult to treat. The Protalex drug (PRTX-001) can actually regulate or
normalize aberrant functions in cells affected by autoimmune disease. Unlike
existing therapy, this permits the tissues to return to a healthy functional
state, slowing or stopping the inflammatory process, and potentially reversing
earlier damage to structures such as joint cartilage. The patent covers the
therapeutic use of PRTX-001 by oral administration or injection, in the
treatment of all of the recognized immune disorders, including many of the
most disabling human diseases such as lupus erythematosus, diabetes mellitus
The Protalex patent forms the basis for the filing of an Investigational
New Drug (IND) application for PRTX-001 with the FDA. Building on highly
successful animal testing recently completed, the company expects to enter
full clinical trials in a number of sites before the end of the year. These
human studies will concentrate on treatment of rheumatoid arthritis, a chronic
and debilitating disease affecting more than 2 million people in the United
States alone. Protalex President John E. Doherty commented, "The Company's
discovery, directed by Dr. Paul L. Mann, has led to an entirely new approach
to the treatment of this devastating disorder. Thousands of people whose
affliction had been thought beyond the reach of medicine can now look forward
not just to relief of symptoms, but perhaps to the reversal of their disease."
After proof of PRTX-001's safety and efficacy in humans, Protalex will seek
FDA approval for its introduction as a prescribed pharmaceutical agent.
Statements in this press release that are not strictly historical are
"forward looking" statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
These statements involve a high degree of risk and uncertainty, are
predictions only and actual events or results may differ materially from those
projected in such forward-looking statements. Factors that could cause or
contribute to differences include the Company's limited operating history,
uncertainty regarding viability and market acceptance of the Company's
products, and the Company's dependence on reimbursement by third parties.
These factors and others are more fully described in the section entitled
"Risks Related to the Company's Business" in the Company's Registration
Statement on Form 10-SB (File No. 00028385) as filed with the Securities and
MAKE YOUR OPINION COUNT - Click Here
SOURCE Protalex, Inc.